Avmapki Fakzynja Co-Pack (Avutometinib / Defactinib)

Avmapki Fakzynja is a cancer treatment for a rare type of ovarian cancer that has come back. It is two medicines packed together: a capsule and a tablet taken by mouth. They work by blocking signals that help the cancer cells grow.

Brand names:Avmapki Fakzynja Co-Pack, Avmapki, Fakzynja
Medication

What people taking Avmapki Fakzynja Co-Pack (Avutometinib / Defactinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Avmapki Fakzynja Co-Pack (Avutometinib / Defactinib) for Epithelial Ovarian Cancer?

NameHow it went

About Avmapki Fakzynja Co-Pack (Avutometinib / Defactinib)

What It's For

Avmapki Fakzynja Co-Pack is a targeted cancer treatment for adults with low-grade serous ovarian cancer that has come back after earlier treatment and whose tumor carries a change (mutation) in a gene called KRAS. The pack holds two separate medicines taken by mouth: avutometinib capsules (Avmapki) and defactinib tablets (Fakzynja). They are approved to be taken together as one regimen. Low-grade serous ovarian cancer is a rare form of ovarian cancer. It usually grows more slowly than the more common high-grade type, but it tends to respond poorly to standard chemotherapy, which leaves fewer good options when it returns. To be eligible, a person must already have had at least one systemic treatment, meaning medicine that acts throughout the body, such as chemotherapy. KRAS status is found by genetic testing of tumor tissue. There is no FDA-approved test made specifically for choosing this treatment, so the cancer team relies on standard tumor sequencing. The FDA granted the combination accelerated approval in 2025, based on how often tumors shrank and how long that lasted. A larger trial comparing it with other standard treatments is underway, and continued approval depends on that trial confirming a real clinical benefit.

How It Works

Many cancers grow because a chain of signals inside the cell, called the MAPK pathway, is stuck switched on. In low-grade serous ovarian cancer this pathway is frequently overactive, and a KRAS mutation is the most common cause in cancer that has returned. Avutometinib acts on two linked proteins in this chain, RAF and MEK, locking them together in an inactive state so the growth signal is weakened. Cancer cells often try to get around this block by turning up a backup signal that runs through a protein called focal adhesion kinase (FAK). Defactinib blocks FAK. In laboratory and animal studies, the two drugs together held back tumor growth more effectively than avutometinib alone, which is why they are given as a pair. They are targeted drugs rather than traditional chemotherapy, but they still affect healthy tissues, especially the eyes, skin, liver and muscles.

Dosage & Administration

Treatment runs in 4-week cycles: both medicines are taken for the first 3 weeks, then there is a week off. Avmapki is taken twice a week, on Day 1 and Day 4 of each week, at the same time of day; each dose is several capsules (four at the usual dose). Fakzynja is one tablet taken twice a day. Both are taken with food and swallowed whole, without chewing, breaking, crushing or opening them. Treatment usually continues for as long as the cancer stays controlled and the side effects remain manageable. Two preventive steps begin with the first cycle. An eye specialist examines the eyes before treatment starts, before the second cycle and then every three cycles. To head off skin reactions, the care team prescribes a steroid cream for the face, scalp, neck, upper chest and upper back, plus an antibiotic taken by mouth, for at least the first two cycles. Missed doses follow different rules for each medicine. An Avmapki dose more than 24 hours late, or a Fakzynja dose more than 6 hours late, is skipped, and the next dose is taken on schedule. Doses are never doubled, and a dose is not repeated after vomiting. Both medicines are kept in the refrigerator in their original bottles. Pauses and dose reductions for side effects are common, and only the prescriber should make them.

Side Effects

Nearly everyone has side effects, and in the main trial most people needed at least one pause in treatment while side effects settled. The most common are nausea, tiredness, diarrhea, vomiting, swelling (edema), muscle and joint aches, stomach pain, indigestion and mouth sores. Skin reactions are almost universal: an acne-like rash, dry or itchy skin, sensitivity to sunlight and sometimes skin infections. Most of these are handled with supportive care or a dose change rather than stopping treatment. About a third of people in the main trial had a serious side effect, most often a severe infection. Eye problems are also common. Blurred vision, dry eyes and floaters can occur, and fluid can collect under the retina, the light-sensing layer at the back of the eye; about 9 in 100 people in the studies had a retinal detachment. Contact the care team promptly about any new or worsening vision change, new floaters or flashes of light, or eye pain or swelling, so an eye specialist can check. Blood tests often show raised liver values and a raised level of CPK (creatine phosphokinase), an enzyme that leaks from damaged muscle. These are usually picked up on routine tests before any symptoms appear, but muscle breakdown (rhabdomyolysis) has occurred and can strain the kidneys. Call the care team promptly for yellowing of the skin or the whites of the eyes, dark or tea-colored urine, pain in the upper right belly, muscle weakness or aches that do not go away, red-brown urine or passing much less urine, or blistering skin, peeling skin or sores in the mouth.

Interactions & Warnings

Stomach acid medicines matter with this treatment. Proton pump inhibitors such as omeprazole (Prilosec) and H2 blockers such as famotidine (Pepcid) reduce how much defactinib the body absorbs and should be avoided. If an antacid is needed, take the Fakzynja tablet 2 hours before or 2 hours after it. Warfarin, a blood thinner, should also be avoided. Bleeding and higher INR results (a blood test of how slowly blood clots) occurred when it was combined with defactinib, so people who need a blood thinner are usually switched to a different one. Several other medicines can raise or lower defactinib levels by changing how the liver breaks it down, so a pharmacist should check every prescription, over-the-counter medicine and supplement before treatment starts and whenever something new is added. This combination can harm a developing baby. A pregnancy test is done before starting if pregnancy is possible. Women who could become pregnant should use effective birth control during treatment and for 1 month after the last dose, and men with a partner who could become pregnant should use it during treatment and for 4 months after. Breastfeeding should stop during treatment and for 2 weeks after the last dose. Animal studies suggest fertility may be reduced, possibly permanently, which is worth discussing before starting. Before starting, tell the care team about any history of eye or retina problems, severe skin reactions or liver disease.

What to Expect

Treatment brings frequent check-ins, especially early on. Blood tests for liver function and CPK are done before each cycle and on day 15 of each of the first four cycles. Eye exams continue every few cycles even when vision seems normal, because some eye changes cause no symptoms at first. Scans show whether the tumor is shrinking, holding steady or growing. In the trial that led to approval, about 44% of people with KRAS-mutated cancer saw their tumors shrink by a meaningful amount, and a few had no visible cancer left on scans. Among those whose tumors shrank, the response lasted anywhere from about 3 months to more than 2 and a half years. In longer follow-up, the typical time before KRAS-mutated cancer started growing again was about a year and a half. These results come from studies without a comparison group, so it is not yet known whether people live longer than with other treatments. Side effects often show up early: eye symptoms typically begin within the first days and skin problems around two weeks in. Many people need a pause or a lower dose at some point. If side effects remain intolerable after one dose reduction of both medicines, the treatment is stopped. Sun protection becomes part of daily life: limit time in the sun, use sunscreen with SPF 30 or higher every day, and wear a hat and covering clothes.

Questions to Ask Your Doctor

  1. 1.How was my tumor tested for a KRAS mutation, and what does the result mean for my treatment options?
  2. 2.How does this combination compare with hormone therapy, chemotherapy or a clinical trial for my cancer?
  3. 3.Which of my current medicines, including acid reducers or a blood thinner, need to change before I start?
  4. 4.Who will do my eye exams, and which eye or skin symptoms should I report the same day?
  5. 5.How will we know whether it is working, and what happens if I need a lower dose or a break?

Last reviewed • Oct 2026

Educational content, not medical advice.